TY - JOUR
T1 - The Spinal Muscular Atrophy Health Index: Italian validation of a disease-specific outcome measure
AU - Sansone, Valeria A.
AU - Pirola, Alice
AU - Lizio, Andrea
AU - Greco, Lucia Catherine
AU - Coratti, Giorgia
AU - Casiraghi, Jacopo
AU - Pane, Marika
AU - Pera, Maria Carmela
AU - Italiano, Cristina
AU - Messina, Sonia
AU - Pozzi, Susanna
AU - Sframeli, Maria
AU - D'Amico, Adele
AU - Bertini, Enrico
AU - Bruno, Claudio
AU - Mauro, Luca
AU - Salmin, Francesca
AU - Stancanelli, Claudia
AU - Pedemonte, Marina
AU - Albamonte, Emilio
AU - Zizzi, Christine
AU - Heatwole, Chad
AU - Mercuri, Eugenio Maria
PY - 2021
Y1 - 2021
N2 - Patient report outcome measures in Spinal Muscular Atrophy (SMA) represent a potential complement to observer rated scales which can be used to better understand treatment response. We developed, translated and validated an Italian version of the Spinal Muscular Atrophy Health Index (SMAHI), a disease-specific, patient reported outcome measure questionnaire, designed to estimate the patients’ perception of disease burden. Test-retest reliability was assessed in 37 patients (16 children aged 12–17 and 21 adults) and was excellent in both cohorts. Internal consistency in an additional 98 patients (24 children, 74 adults) was also excellent (Cronbach's alpha = 0.93 and 0.91 respectively). In children the highest level of disease burden was generated from lower limb dysfunction and fatigue as well as their perception of decreased performance in social situations. Most patients in the adult cohort were sitters and complained of problems with upper limb functions as well as of fatigue. The SMAHI-IT was also able to differentiate between SMA types according to diseases severity. The results of our study demonstrate that the SMAHI can be considered a marker of disease-specific burden in patients with SMA with a high test-retest reliability and internal validity in Italian patients aged 12 and older.
AB - Patient report outcome measures in Spinal Muscular Atrophy (SMA) represent a potential complement to observer rated scales which can be used to better understand treatment response. We developed, translated and validated an Italian version of the Spinal Muscular Atrophy Health Index (SMAHI), a disease-specific, patient reported outcome measure questionnaire, designed to estimate the patients’ perception of disease burden. Test-retest reliability was assessed in 37 patients (16 children aged 12–17 and 21 adults) and was excellent in both cohorts. Internal consistency in an additional 98 patients (24 children, 74 adults) was also excellent (Cronbach's alpha = 0.93 and 0.91 respectively). In children the highest level of disease burden was generated from lower limb dysfunction and fatigue as well as their perception of decreased performance in social situations. Most patients in the adult cohort were sitters and complained of problems with upper limb functions as well as of fatigue. The SMAHI-IT was also able to differentiate between SMA types according to diseases severity. The results of our study demonstrate that the SMAHI can be considered a marker of disease-specific burden in patients with SMA with a high test-retest reliability and internal validity in Italian patients aged 12 and older.
KW - Internal validity
KW - Patient-reported outcomes
KW - Spinal muscular atrophy
KW - Spinal muscular atrophy health index
KW - Test-retest reliability
KW - Internal validity
KW - Patient-reported outcomes
KW - Spinal muscular atrophy
KW - Spinal muscular atrophy health index
KW - Test-retest reliability
UR - http://hdl.handle.net/10807/182752
U2 - 10.1016/j.nmd.2021.02.006
DO - 10.1016/j.nmd.2021.02.006
M3 - Article
SN - 0960-8966
VL - 31
SP - 409
EP - 418
JO - Neuromuscular Disorders
JF - Neuromuscular Disorders
ER -